Merck KGaA MRK StarRatingValueLabel_4Julie Utterback, CFA - Senior Equity Analyst - Morningstar Inc.

Last Price
150.80
Day Change
-1.55|-1.02%

As of 25/04/2024
09:29:44 CEST | EUR  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
150.70 - 150.80150.45 - 152.0514,948290,79566.24Bil
Last Close52 Week RangeP/EYield %ISIN
152.35134.30 - 172.4022.761.48DE0006599905

Merck KGaA Share Price

Morningstar's Take MRK

Merck KGaA has made a series of acquisitions and divestitures in the past decade or so to position the group for solid long-term growth in three key segments: life sciences, electronics, and healthcare. So although Merck is in the middle of a reset period following the pandemic boom years and although the biopharmaceutical pipeline has experienced a setback with evobrutinib (multiple sclerosis), we continue to have a positive view of the company's long-term prospects.

Fair Value Estimate

171.00 EUR

Uncertainty

Average

Economic Moat

Narrow
There is no one analyst in which a Quantitative Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here.
Julie Utterback, CFA - Senior Equity Analyst - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Financials
202120222023
more...
Income Statement
Revenue19,687.0022,232.0020,993.00
Operating Income4,196.004,752.003,577.00
Net Income3,055.003,326.002,824.00
Basic EPS7.037.656.49
Avg. Diluted Shares Outstanding435435435
Balance Sheet
Current Assets10,982.0012,201.0012,393.00
Non Current Assets34,380.0036,325.0036,102.00
Total Assets45,362.0048,526.0048,495.00
Current Liabilities10,432.009,513.008,699.00
Total Liabilities---
Total Equity21,338.0025,927.0026,680.00
Cash Flow
Operating Cash Flow4,616.004,259.003,784.00
Capital Expenditure-1,421.00-1,806.00-2,023.00
Free Cash Flow3,195.002,453.001,761.00

In millions, except "Basic EPS". Currency is EUR.

Company Profile

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Stock Style

Large-Blend

Fiscal Year Ends

December

Employees

62,908
Key Stats
more...
Price/Earning TTM23.47
Price/Book2.48
Price/Sales TTM3.16
Rev Growth (3 year avg)6.19
EPS Growth (3 year avg)-
Operating Margin % TTM17.04
Net Margin % TTM13.45
ROE TTM10.74
Debt/Equity0.35
Dividends
PreviousLatest
Declared Date07/03/2302/02/24
Ex-Div02/05/2329/04/24
Paid04/05/2302/05/24
Amnt2.202.20
Julie Utterback, CFA - Senior Equity Analyst - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures